The Food and Drug Administration approved a drug this week that roughly doubles median survival in metastatic pancreatic cancer, a disease that has resisted nearly every advance oncology has produced in fifty years. Rasonque, known generically as daraxonrasib, is the first RAS targeted therapy cleared for pancreatic adenocarcinoma. In its pivotal trial, patients lived a median of 13.2 months against 6.7 months on standard chemotherapy. The FDA cleared it six and a half months ahead of schedule.
What Was Approved and for Whom
The approval, announced August 26, covers adults with metastatic pancreatic adenocarcinoma who have already received systemic therapy or who cannot tolerate multiagent chemotherapy. The drug comes from Revolution Medicines and is taken as a once daily oral tablet.
Pancreatic adenocarcinoma accounts for roughly 90 to 95 percent of the approximately 67,000 pancreatic cancer cases diagnosed in the United States each year. It is the form of the disease most people mean when they say pancreatic cancer, and it is the one with the worst outlook.
The Survival Numbers
In the RASolute 302 trial, which enrolled 500 patients, median overall survival reached 13.2 months on daraxonrasib compared with 6.7 months on chemotherapy. Median progression free survival was 7.2 months against 3.6 months.
Both figures roughly doubled. In an oncology landscape where new approvals often turn on gains of a few weeks, a doubling of median survival in this particular cancer is a different order of result.
Why RAS Matters Here
The RAS family of genes has been called the most consequential target in cancer biology and, for decades, the most undruggable. Mutated RAS drives an enormous share of pancreatic cancers, and the protein’s shape long resisted every attempt to design a molecule that could grip it.
Among patients with RAS G12 mutations, the trial reported a 60 percent reduction in the risk of death. That is the subgroup where the biology and the drug line up most directly, and it is the strongest signal in the dataset.
What the FDA Said
Acting FDA Commissioner Kyle Diamantas framed the approval around the population it serves. “Today’s approval provides a critical new option for patients facing an extraordinarily difficult and historically hard to treat cancer,” he said.
Dr. Angelo de Claro, director of the agency’s Oncology Center of Excellence, was more direct about the data. “This drug showed unprecedented results in an area of high unmet need,” he said. The early clearance, six and a half months before the scheduled decision date, reflects that assessment.
The Necessary Caution
Doctors treating the disease have been careful not to oversell it. Dr. Andrew Coveler of the Fred Hutch Cancer Center offered the framing that matters most for patients and families: “This medicine is not a cure but a significant improvement.”
Thirteen months is still thirteen months. The drug extends life meaningfully in a disease where almost nothing has, and it does not change the fundamental trajectory for most patients. Both things are true, and anyone reading this because of a diagnosis in their family should hear both.
Side Effects and Tolerability
The most common adverse effects reported were rash, diarrhea, stomatitis, nausea, fatigue, vomiting, and abdominal pain. None of that is trivial.
The notable finding is comparative: patients discontinued daraxonrasib because of side effects less often than patients discontinued chemotherapy. For a population that is frequently too weakened by the disease to tolerate aggressive treatment, a therapy people can actually stay on is part of the benefit rather than a footnote to it.
The Price Question
The Associated Press reported a list price of roughly 39,800 dollars for a one month supply. That figure comes from a single outlet and should be treated as preliminary until the company or payers confirm it.
List price is also not what most patients pay. Coverage decisions by Medicare and commercial insurers, plus manufacturer assistance programs, will determine actual access, and those decisions take months to settle. The gap between an approval and a prescription someone can afford is where a lot of these stories go quiet.
What It Signals for the Field
If a RAS targeted drug works in pancreatic cancer, the same target sits underneath large fractions of colorectal and lung cancer as well. Revolution Medicines and others have programs running in those settings, and this approval will accelerate them.
It also arrives during a period of visible strain elsewhere in American public health, including the measles deaths recorded in Lancaster County this month. Progress in one part of the system does not offset failure in another, but it is worth noting that the drug development pipeline is still producing results of this magnitude.
The approval also lands as a test of how quickly the system can move when the data is strong enough. Six and a half months ahead of the scheduled decision date is a substantial acceleration, and it happened without the trial being cut short or the endpoints being softened. The 500 patient study ran to a hard overall survival readout, which is the highest bar in oncology and the one regulators most often waive in favor of surrogate measures.
For patients currently in treatment, the practical questions are logistical rather than scientific. Which centers will have it first, how quickly oncologists integrate it into treatment sequencing, and whether prior therapy requirements in the label limit who qualifies. Anyone facing this diagnosis should raise it with their oncology team directly rather than drawing conclusions from a trial summary.
Pancreatic cancer has produced a long series of headlines over the years that did not survive contact with clinical practice. This one has a completed randomized trial and a regulatory approval behind it, which puts it in a different category. It still needs to work outside a trial population.
Frequently Asked Questions
What drug did the FDA approve?
Rasonque, generically daraxonrasib, from Revolution Medicines. It is the first RAS targeted therapy approved for metastatic pancreatic adenocarcinoma.
How much does it extend survival?
Median overall survival was 13.2 months versus 6.7 months on chemotherapy in the RASolute 302 trial of 500 patients.
Who is eligible for it?
Adults with metastatic pancreatic adenocarcinoma who have had prior systemic therapy or cannot tolerate multiagent chemotherapy.
Is it a cure?
No. Physicians involved have been explicit that it is a significant improvement in survival, not a cure.
What are the side effects?
Rash, diarrhea, stomatitis, nausea, fatigue, vomiting, and abdominal pain were most common. Discontinuation was less frequent than with chemotherapy.
What does it cost?
The Associated Press reported roughly 39,800 dollars for a one month supply. Insurance coverage and assistance programs will determine what patients actually pay.
